Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$19.32 ▲ +0.03
(+0.16%)
MKT CAP: $3.09B • VOL: 1.45M
52W L $14 52W H $27
CASH DIVIDEND YIELD
0.00%
ANNUAL RATE: $0.00 / SH
TOTAL SHAREHOLDER YIELD
1.85%
BUYBACK YIELD: 1.85%
FCF PAYOUT COVERAGE RATIO
0.0%
GAAP EPS PAYOUT: 0.0%
DIVIDEND SAFETY SCORE NO DIVIDEND
50/100
GROWTH STREAK: 0 CONSECUTIVE YRS
DNLI // EX-DIVIDEND & CAPITAL DISTRIBUTION SCHEDULE (DIV <GO>)
SPOT: $19.32
Denali Therapeutics Inc. (DNLI) DOES NOT CURRENTLY DISTRIBUTE A REGULAR CASH DIVIDEND. CAPITAL ALLOCATION PRIORITIZES INTERNAL R&D (-35.0% ROIC) AND OPPORTUNISTIC SHARE REPURCHASES (1.85% BUYBACK YIELD).